Due: October 8, 2025 The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) focused on surveying current industry capabilities in the engineering, testing, and manufacturing of solutions capable of neutralizing a Read More
Due: September 2, 2025 Preventative treatments and vaccines offer proactive solutions to biological threats: however, many of the current countermeasures are decades old. These prophylactic platforms have stagnated through single threat targeting which is potentiated Read More
Due: September 2, 2025 The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) supports the warfighter by developing medical countermeasures against a wide range of threats, including marine toxins. Exposure Read More
Due: August 4, 2025 The DxR2 program will solicit new point of care/remote-use products with domestic manufacturing capabilities which address test development for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) biothreats to include glanders, botulism, Read More
Due: December 15, 2025 The TechConnect Critical Technology Challenge: Biotech and Medical is a premier open innovation program designed to accelerate solutions to the most pressing challenges in biotechnology and medical innovation. Aligned with the critical technology Read More
Due: August 8, 2025 The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN P) is conducting market research to identify innovative solutions that address the persistent challenge of contaminant infiltration at Read More
Due: August 15, 2025 The Cognitive Neuroscience (CogNeuro) program seeks to fund proposals that can advance our understanding of the neural mechanisms underlying human cognition and behavior. Funded proposals typically relate precise and rich quantifications Read More
Due: August 14, 2025 The goal of this funding opportunity announcement is to generate brain region and cell-type specific microglial protein profiles in the context of HIV and SUD, then use those molecular profiles and Read More
Due: August 14, 2025 This broad RFA will support exploratory studies addressing mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including HAND) in the context of SUDs.
Due: August 27, 2025 The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery. Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.